NCT05597410 Shanghai At Risk for Alzheimer's Disease: a Cohort Study
| NCT ID | NCT05597410 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Ruijin Hospital |
| Condition | Alzheimer Disease |
| Study Type | OBSERVATIONAL |
| Enrollment | 3,418 participants |
| Start Date | 2022-03-01 |
| Primary Completion | 2029-03 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 3,418 participants in total. It began in 2022-03-01 with a primary completion date of 2029-03.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The goal of this cohort study is to estimate the incidence of AD in the first-degree relatives of patients with AD. The main questions it aims to answer are: * cognitive changes of subjects at high risk of AD as ageing; * environmental and behavioral factors affecting AD incidence.
Eligibility Criteria
Inclusion Criteria: 1. the AD diagnostic criteria of probands meet the 2011 National Institute on Aging - Alzheimer's Association framework, and participants are the first-degree relatives (including parents, children and siblings of the same father and mother) of the proband; 2. not patients with dementia; 3. ≥ 50 years, males and females; 4. subjects have lived in Shanghai for more than 1 year and have no plan to move out of Shanghai within 5 years; 5. subjects are able to complete investigation, physical examination, imaging examination and biological specimen collection. Exclusion criteria: Individuals will be excluded if they have: 1. other diseases which could cause cognitive decline, e.g. cerebrovascular diseases, Creutzfeldt-Jakob disease and Parkinsons disease; 2. history of psychological disorders (according to Diagnostic and Statistical Manual of Mental Disorders, 5th Edition); 3. uncorrectable visual or auditory impairment that hampers the completion of related examination. 4. pre-menopausal women will also be excluded.
Contact & Investigator
Gang Wang, MD, PhD
STUDY CHAIR
Ruijin Hospital
Frequently Asked Questions
Who can join the NCT05597410 clinical trial?
This trial is open to participants of all sexes, aged 50 Years or older, studying Alzheimer Disease. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT05597410 currently recruiting?
Yes, NCT05597410 is actively recruiting participants. Contact the research team at wg11424@rjh.com.cn for enrollment information.
Where is the NCT05597410 trial being conducted?
This trial is being conducted at Shanghai, China.
Who is sponsoring the NCT05597410 clinical trial?
NCT05597410 is sponsored by Ruijin Hospital. The principal investigator is Gang Wang, MD, PhD at Ruijin Hospital. The trial plans to enroll 3,418 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.